Research programme: antibacterials - Acurx Pharmaceuticals
Alternative Names: Antibacterial agents - Acurx Pharmaceuticals; Antibiotics - Acurx Pharmaceuticals; CCP3; Multi-drug resistant antibacterials - Acurx PharmaceuticalsLatest Information Update: 03 Mar 2025
At a glance
- Originator Acurx Pharmaceuticals
- Class Antibacterials; Small molecules
- Mechanism of Action DNA polymerase III inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Skin and soft tissue infections
- Research Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Streptococcal infections; Vancomycin-resistant enterococcal infections
Most Recent Events
- 19 Feb 2025 Preclinical trials in Skin and soft tissue infections in USA (PO) prior to February 2025
- 19 Jul 2023 Early research is ongoing for for research development in Streptococcal-infections in USA (Parenteral) (Acurx Pharmaceuticals pipeline, June 2023)
- 19 Jul 2023 Early research is ongoing for research development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (Parenteral) (Acurx Pharmaceuticals pipeline, June 2023)